<DOC>
	<DOC>NCT01526057</DOC>
	<brief_summary>In this study, patients with moderate to severe rheumatoid arthritis who are being treated with methotrexate will receive 2 intravenous treatments with either PF-05280586 or Rituxan (Rituximab) or MabThera (Rituximab). During the course of the study, the effects of the drugs will be assessed by sampling the levels of drug in the blood, blood cell counts, and by comparing these levels among the different treatments. Safety, tolerability and immunologic response also will be evaluated throughout.</brief_summary>
	<brief_title>A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Confirmed diagnosis of rheumatoid arthritis Meets Class I, II or III of the ACR 1991 Revised Criteria RA seropositivity Stable dose of methotrexate Inadequate response to TNF inhibitors Any prior treatment with lymphocyte depleting therapies History of active TB infection Known or screen test positive for specific viruses or indicators of viral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>rituximab</keyword>
	<keyword>methotrexate</keyword>
	<keyword>anti-TNF</keyword>
</DOC>